Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Oct;3(10):790-2.
doi: 10.1002/ccr3.342. Epub 2015 Aug 26.

Anticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria

Francesco Dragoni  1 , Flavia Chiarotti  2 , Laura Lombardi  1 , Anna Paola Iori  1 , Arturo Cafolla  1
Affiliations
Case Reports

Anticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria

Francesco Dragoni et al. Clin Case Rep. 2015 Oct.

Abstract

The new direct oral anticoagulants such us rivaroxaban, could play an important role in the anticoagulant treatment of patients with paroxysmal nocturnal hemoglobinuria where anticoagulant treatment is complex to run, since they have shown a reduction in serious bleeding complications compared to antithrombotic therapy with classical vitamin k antagonist.

Keywords: Anticoagulant therapy; bleeding complication; paroxysmal nocturnal hemoglobinuria; rivaroxaban; thrombosis.

PubMed Disclaimer

References

    1. Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria. Haematologica. 2000;85:82–87. - PubMed
    1. Socie G, Gramont A, Rio B, Leporrier M, Rose C, Heudier P, et al. Paroxysmal nocturnal haemoglobinuria: long term follow-up and prognostic factors. Lancet. 1996;348:573–577. - PubMed
    1. Hillmen P, Muus P, Duhrsen U, Risitano AM, Schulbert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123–4128. - PubMed
    1. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008;358:2765–2775. - PubMed
    1. Prins MH, Lensing AWA, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. and on behalf of the EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb. J. 2008;20:11–21. - PMC - PubMed

Publication types

LinkOut - more resources